Bio-Techne Corp (TECH) Social Stream



Bio-Techne Corp (TECH): $348.50

2.49 (+0.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TECH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

BIO-TECHNE Corp (TECH) Price Targets From Analysts

Use the tables below to see what analysts covering BIO-TECHNE Corp think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-02 9 $600 $400 $510.625 $433.04 17.92%
2021-12-01 9 $600 $400 $511.875 $433.04 18.21%
2022-02-01 9 $600 $400 $506.25 $433.04 16.91%
2022-03-01 6 $600 $540 $565 $433.04 30.47%

The Trend in the Analyst Price Target


Over the past 44 weeks, TECH's average price target has gone up $142.22.

Over the past 47 weeks, TECH's average upside potential has been 10.84%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-13 8 500 410 453.890 443.94 2.24%
2021-06-26 8 500 410 453.890 436.54 3.97%
2021-09-04 8 590 490 540.670 513.09 5.38%
2021-11-02 9 600 400 510.625 503.33 1.45%
2022-02-01 7 600 410 542.500 401.57 35.09%

TECH Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 6 0 0 0 0 6

The Trend in the Broker Recommendations


TECH's average broker recommendation rating improved by 0.73 over the prior 151 days.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • BIO-TECHNE Corp's average analyst price target is greater than 687.53% of all US stocks.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, BIO-TECHNE Corp's upside potential (average analyst target price relative to current price) is greater than 76.29% of them.
  • TECH has a higher number of analysts covering the stock than 159.9% of stocks in the large market cap category.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, BIO-TECHNE Corp's variance in analysts' estimates is lower than -72.42% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to BIO-TECHNE Corp are SGEN, RGEN, and QGEN.

What is the outlook for TECH? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7314 seconds.